| Literature DB >> 29215607 |
Tiago Clemente1,2, Narcisio J Vieira1,2, Juan P Cerliani3, Colin Adrain4, Alexander Luthi5, Mariana R Dominguez6, Monica Yon1,2, Fernanda C Barrence7, Thalita B Riul8, Richard D Cummings9, Telma M Zorn7, Sebastian Amigorena10, Marcelo Dias-Baruffi8, Maurício M Rodrigues6, Seamus J Martin5, Gabriel A Rabinovich3,11, Gustavo P Amarante-Mendes1,2,5.
Abstract
Secretory granules released by cytotoxic T lymphocytes (CTLs) are powerful weapons against intracellular microbes and tumor cells. Despite significant progress, there is still limited information on the molecular mechanisms implicated in target-driven degranulation, effector cell survival and composition and structure of the lytic granules. Here, using a proteomic approach we identified a panel of putative cytotoxic granule proteins, including some already known granule constituents and novel proteins that contribute to regulate the CTL lytic machinery. Particularly, we identified galectin-1 (Gal1), an endogenous immune regulatory lectin, as an integral component of the secretory granule machinery and unveil the unexpected function of this lectin in regulating CTL killing activity. Mechanistic studies revealed the ability of Gal1 to control the non-secretory lytic pathway by influencing Fas-Fas ligand interactions. This study offers new insights on the composition of the cytotoxic granule machinery, highlighting the dynamic cross talk between secretory and non-secretory pathways in controlling CTL lytic function.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29215607 PMCID: PMC5827204 DOI: 10.1038/cddis.2017.506
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469
Figure 1Proteomic analysis of cytotoxic cell granules. (a) Proteomic strategy; (b) 1D gel analysis of cytotoxic granules and main proteins detected by mass spectrometry
List of the most abundant proteins identified in 1D SDS-PAGE sample of CTL granule preparation
| Accession no. | MW/pI | Coverage (%) | Matched peptides | |
|---|---|---|---|---|
| Heat-shock protein HSP90-beta (TSTA) | P11499 | 83 326/5.0 | 42 | 24 |
| NEDD1 protein | P33215 | 72 970/8.3 | 23 | 11 |
| BIP/GRP78 | P20029 | 72 423/5.1 | 59 | 38 |
| Heat-shock cognate 71 kDa protein | P08109 | 70 872/5.4 | 50 | 36 |
| Perforin | P10820 | 62 082/8.4 | 39 | 25 |
| T-complex protein 1/TCP-1 theta/CCT-theta | P42932 | 59 556/5.4 | 37 | 17 |
| Zinc finger protein 94 (Zfp-94) | Q9Z1D9 | 59 156/7.8 | 35 | 18 |
| Pyruvate kinase, M2 isozyme | P52480 | 57 888/7.2 | 50 | 31 |
| Protein disulfide isomerase A3 precursor (ERp60) | P27773 | 56 622/6.0 | 46 | 23 |
| Alpha enolase/Enolase-1 | P17182 | 47 141/6.4 | 55 | 27 |
| DNAse gamma/DHP2/LS-DNAse/DNAse I-like 3 | O55070 | 35 760/8.9 | 40 | 14 |
| Purine nucleoside phosphorylase/Inosine phosphorylase | P23492 | 32 277/5.8 | 54 | 18 |
| Granzyme A precursor/TSP-1/CTLA-3 | P11032 | 28 599/9.5 | 61 | 19 |
| Phosphomannomutase 2 (PMM 2) | Q9Z2M7 | 27 657/6.0 | 61 | 15 |
| Granzyme F precursor/MCSP-3/CCP4 | P08883 | 27 643/9.9 | 40 | 11 |
| Granzyme E precursor/CCP3 | P08884 | 27 494/9.7 | 49 | 13 |
| Granzyme B/CTLA-1/CCP1 | P04187 | 27 470/9.8 | 50 | 15 |
| Granzyme G precursor/MCSP-1 | P13366 | 27 381/9.6 | 61 | 13 |
| Granzyme C/CCP2 | P08882 | 27 311/9.3 | 62 | 17 |
| Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) | Q9R0P9 | 24 838/5.1 | 40 | 10 |
| Ras-related Rab-17 | P35292 | 23 640/5.4 | 39 | 7 |
| Ras-related protein Rab-2A | P53994 | 23 548/6.1 | 57 | 9 |
| PPIase precursor/Rotamase/Cyclophilin B | P24369 | 22 713/9.5 | 56 | 15 |
| Peroxiredoxin 1 (thioredoxin peroxidase 2) | P35700 | 22 177/8.3 | 41 | 9 |
| 60S ribosomal protein L9 | P51410 | 21 882/10 | 58 | 12 |
| Ferritin light chain 1 | P29391 | 20 803/5.7 | 46 | 7 |
| Adenine phosphoribosyltransferase/APRT | P08030 | 19 763/6.3 | 58 | 9 |
| Translationally controlled tumor protein (TCTP) | P14701 | 19 462/4.8 | 42 | 12 |
| 40S ribosomal protein S10 | P09900 | 18 916/10.2 | 70 | 14 |
| Cofilin | P18760 | 18 560/8.2 | 69 | 12 |
| PPIase/Rotamase/Cyclophilin A | P17742 | 17 972/7.7 | 45 | 12 |
| 40S ribosomal protein S16 | P14131 | 16 356/10.2 | 68 | 11 |
| Superoxide dismutase [Cu-Zn] | P08228 | 15 943/6.0 | 54 | 9 |
| Myosin light chain alkali (MLC3nm) | Q60605 | 15 731/4.8 | 62 | 8 |
| Cystatin C | P21460 | 15 531/9.2 | 53 | 6 |
| Profilin I | P10924 | 14 957/8.5 | 46 | 8 |
| Galectin-1 | P10812 | 14 866/5.3 | 62 | 10 |
| Histone H2A | P22752 | 14 182/10.9 | 63 | 7 |
| Histone H2B | P10854 | 13 936/10.3 | 65 | 18 |
List of proteins identified by 2D electrophoresis of CTL granule preparation
| 1 | Q62261 | 27 4425/5.7 | 27 | 65 | |
| 2 | P20029 | 72 423/5.1 | 54 | 26 | |
| 3 | P08109 | 70 872/5.4 | 36 | 20 | |
| 4 | 75 kDa glucose regulated protein (GRP 75)/Mortalin | P38647 | 73 529/5.9 | 19 | 8 |
| 5 | Vimentin | P20152 | 53 688/5.1 | 21 | 12 |
| 6 | Calreticulin/calregulin/ERP60 | NP_031617 | 48 136/4.33 | 53 | 24 |
| 7 | Calreticulin/calregulin/ERP60 | NP_031617 | 48 136/4.33 | 54 | 23 |
| 8 | P27773 | 56 622/6.0 | 42 | 20 | |
| 9 | Angiopoietin-related protein 2 precursor | Q9R045 | 57 119/7.3 | 20 | 7 |
| 10 | P17182 | 47 453/6.4 | 76 | 34 | |
| 11 | P17182 | 47 453/6.4 | 45 | 18 | |
| 12 | Cathepsin D precursor | P18242 | 44 954/6.7 | 34 | 13 |
| 13 | Cathepsin D precursor | P18242 | 44 954/6.7 | 34 | 12 |
| 14 | NP_001092 | 42 052/5.29 | 42 | 12 | |
| 15 | Aldose reductase | P45376 | 35 733/6.7 | 24 | 7 |
| 16 | NUDIX | NP_705789 | 35 623/9.15 | 38 | 13 |
| 17 | P08884 | 27 494/9.7 | 26 | 5 | |
| 18 | P11032 | 28 599/9.5 | 41 | 9 | |
| 19 | P11032 | 28 599/9.5 | 57 | 17 | |
| 20 | P11032 | 28 599/9.5 | 46 | 10 | |
| 21 | Chloride intracellular channel protein 1/NCC27/p64 CLCP | Q9Z1Q5 | 27 013/5.1 | 44 | 9 |
| 22 | Chloride intracellular channel protein 1/NCC27/p64 CLCP | Q9Z1Q5 | 27 013/5.1 | 39 | 9 |
| 23 | Proteasome subunit alpha type 1/Macropain subunit C2 | Q9R1P4 | 29 547/6.0 | 34 | 9 |
| 24 | Ubiquitin carboxyl-terminal hydrolase isozyme L3 (UCH-L3) | Q9JKB1 | 26 152/5.0 | 43 | 7 |
| 25 | Phosphoglycerate mutase 1/PGAM-B | Q9DBJ1 | 28 832/6.7 | 59 | 13 |
| 26 | P08882 | 27 311/9.3 | 75 | 25 | |
| 27 | Triosephosphate isomerase/TIM | P17751 | 26 713/6.9 | 48 | 13 |
| 28 | Triosephosphate isomerase/TIM | P17751 | 26 713/6.9 | 40 | 9 |
| 29 | P14701 | 19 462/4.8 | 37 | 8 | |
| 30 | P14701 | 19 462/4.8 | 44 | 12 | |
| 31 | P08030 | 19 763/6.3 | 58 | 8 | |
| 32 | P04187 | 27 470/9.8 | 30 | 7 | |
| 33 | Nucleoside diphosphate kinase B (NDK B)/ NM23-M2 | Q01768 | 17 363/7.0 | 68 | 9 |
| 34 | P17742 | 17 972/7.7 | 50 | 9 |
Also identified by 1D electrophoresis.
Figure 2Confocal and electron microscopy of YT cells. (a) Confocal microscopy showing colocalization of Gal1 with granzyme B, perforin, Lamp-1 and Lamp-2; (b) electron microscopy showing Gal1 localization inside cytotoxic granules
Figure 3Altered cytotoxic activity of Lgals1 CD8+ T cells. (a) In vivo antigen-specific target elimination by WT or Lgals1 C57BL/6 mice immunized or not with 2 × 108 PFU of Ad5β-gal 8 days before. (b) In vitro killing of L1210 targets by CD8 T cells obtained from the peritoneal cavity of WT or Lgals1 C57BL/6 mice injected 12 days before with L1210 cells. (c and d) WT or Lgals1CD8 T-cell degranulation upon antigen-specific stimulation, as measured by Lamp-1 (CD107a) externalization
Figure 4Lgals1 CD8+ T cells displayed enhanced in vitro and in vivo proliferating capacity compared to WT cells. (a and b) ELISPOT analysis of IFN-γ-producing lymph node cells obtained from WT or Lgals1 C57Bl/6 mice immunized or not with Ad5.βgal for 7 days and in vitro stimulated with cognate peptide ICP. (c) Antigen-specific CD8 T cells obtained from spleens of WT or Lgals1 C57Bl/6 mice immunized or not with Ad5.βgal for 7 days, assessed as pentamer-positive events. (d–f) In vitro proliferation of WT or Lgals1 CD8 T cells stimulated for 72 h with 40 U/ml IL-2 and 10 μl/ml of CD3/CD28 beads. (d) Histogram represents the peaks of CFSE dilution of dividing cell populations. Bars represent (e) average stage of division and (f) percentage of cells in different stages of divisions in response to stimulation by IL-2 and anti-CD3/anti-CD28 mAb as determined from the CFSE dilution profile in d
Figure 5Lgals1 CD8+ T cells are as efficient as WT CD8+ T cells at killing peptide-pulsed FAS-deficient target cells. (a) In vivo cytotoxic assay comparing the efficiency of WT or Lgals1 mice to eliminate Fas-sufficient or -deficient target cells. (b) Colocalization of FasL and Gal1 in YT cells by confocal microscopy. (c) Co-immunoprecipitation followed by immunoblotting of Gal1 and FasL expression in lysates from CD8 purified cells incubated with anti-CD3 and anti-CD28 mAb for 18 h and further stimulated (+) or not (−) with recombinant Gal1 (rGal1). Input, whole cell lysate; IP, immunoprecipitation. Ponceau S staining of all the proteins ran is shown (upper panel). (d and e) Flow cytometry analysis of FasL expression in non-permeabilized, purified CD8+ T cells incubated or not with anti-CD3/anti-CD28 mAb for 18 h and then stimulated with PBS or rGal1 for the indicated time periods. Nonspecific binding determined with isotype-matched control antibodies is shown. (d) Curves of rMFI (median fluorescence intensity of specific marker signal–median fluorescence intensity of unspecific signal) for each time period analyzed. (e) Retention of FasL on the surface of purified CD8+ T cells. Numbers show the percentage of positive cells